Production (Stage)
Enanta Pharmaceuticals, Inc.
ENTA
$7.50
$0.091.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.32% | 33.28% | -2.55% | 42.00% | 17.26% |
| Total Depreciation and Amortization | 93.72% | 38.47% | -28.40% | -8.76% | 15.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.62% | -51.01% | 2,460.22% | -38.89% | -16.45% |
| Change in Net Operating Assets | 163.04% | 108.18% | 47.62% | 318.93% | -119.67% |
| Cash from Operations | 52.84% | 32.76% | 51.86% | 54.01% | -107.51% |
| Capital Expenditure | -52.16% | -1,011.18% | -554.31% | -204.14% | 30.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -103.04% | 729.75% | 112.24% | 100.14% | 22.67% |
| Cash from Investing | -107.45% | 625.30% | 61.14% | 95.65% | 25.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 13.57% | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -- | -86.00% | -94.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -31.93% | 30.88% | -31,565.22% | -103.34% | 343.21% |
| Cash from Financing | -7.37% | 32.16% | -31,269.57% | -103.33% | -216.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -204.81% | 203.65% | 114.89% | -226.22% | -23.73% |